The honest headline should have been. Metformin fails to benefit metabolically normal breast cancer patients. “Patients with ERBB2+ breast cancer in the metformin group vs the placebo group had longer invasive disease–free survival (metformin, 1.93 events per 100 patient-years vs placebo, 3.05 events per 100 patient-years; HR, 0.64; 95% CI, 0.43-0.95; P = .03) and had longer overall survival (
Excellent analysis by you. I am in complete agreement with you. Frankly I do not agree with the study's data interpretation/duration for data extraction.incidentally, it is either my insight or mistake at the breast and prostate are "comparable" and that metformin would be of benefit and prostate cancer. H Robert Silverstein MD FACC
Not surprised! The entire industry is corrupt to its core. They go by their preordained narratives then cherry-picking the data to fit it somehow to the point of absurdity!
Excellent analysis by you. I am in complete agreement with you. Frankly I do not agree with the study's data interpretation/duration for data extraction.incidentally, it is either my insight or mistake at the breast and prostate are "comparable" and that metformin would be of benefit and prostate cancer. H Robert Silverstein MD FACC
Thanks Bob. It is encouraging that you find this information useful.
Not surprised! The entire industry is corrupt to its core. They go by their preordained narratives then cherry-picking the data to fit it somehow to the point of absurdity!